Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications
Shots:
- Merck reported the discontinuation of the clinical development program for vibostolimab and favezelimab which were being evaluated in a fixed dose with Keytruda under the KeyVibe and KEYFORM programs
- Vibostolimab being developed in the P-III (KeyVibe-003, KeyVibe-007, and KeyVibe-006) studies among NSCLC patients was discontinued by the recommendation of an independent Data Monitoring Committee (DMC)
- Furthermore, the P-III (KEYFORM-008) study of favezelimab for classical Hodgkin lymphoma (cHL) patients was also discontinued, but data analysis is ongoing, and Merck will share the results with the scientific community
Ref: Merck | Image: Merck
Related News:- Merck Reports the US FDA’s BLA Acceptance of Clesrovimab to Protect Infants from RSV Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
